GCC 1366: A Prospective Study of Neoadjuvant Non-Steroidal Aromatase Inhibitors to Evaluate Anti-Proliferative Response in Obese and Overweight Patients
试验速览
- 阶段
- 不适用
- 状态
- 终止
- 入组人数
- 42
- 试验地点
- 1
- 主要终点
- Percent Change in Proliferative Index (Ki67) After Treatment With the Standard Dose Anastrozole or Letrozole in Normal, Obese, and Overweight Patients
研究概览
简要总结
More than three quarter of patients with breast cancer are treated by hormone pills called tamoxifen and aromatase inhibitors (AIs). AIs are drugs that stop female hormone production. This hormone production mostly happens in fat, muscle, and breast tissue in postmenopausal women. The female hormone estrogen is an important hormone for the growth of breast cancer cells. Anastrozole (Arimidex®) and Letrozole (Femara®) are AIs that are approved by the Food and Drug Administration (FDA). They have been used since 2005 to treat women with early stage breast cancer.
When given before surgery (neoadjuvant), both anastrozole and letrozole have been shown to successfully shrink breast cancer tumors in most patients. In over 50% of patients, anastrozole and letrozole when given for about 4 months also helped to improve surgery outcomes. On top of that, whether or not a patient responds to anastrozole and letrozole before surgery can help the doctor decide whether that patient needs additional chemotherapy.
One of the things may influence the level of hormone is body weight. It has been previously shown that postmenopausal women with higher body fat have higher level of female hormone as well as an increased risk of breast cancer. This is likely due to an increase in aromatase activity in the fatty tissue. However, at the current time AIs are used at the same doses in all women with breast cancer no matter whether they have different body weight. Currently, we do not know for certain whether the same doses of AIs work as well in patients with higher body fat compared to patients with less body fat.
The purpose of this study is to see if women with higher body fat respond differently to AI treatment compared to women with lower body fat.
详细描述
GCC 1366 is a prospective randomized window trial to evaluate the anti-proliferative response in obese and overweight breast cancer patients treated with neoadjuvant non-steroidal aromatase inhibitors. Post-menopausal women over the age of 18 years with estrogen receptor positive Her 2 neu negative stage II-III breast cancer are eligible. Participants will be randomized according to BMI to neoadjuvant treatment with Arimidex or Letrozole.
A total of 90 patients will be enrolled with 15 patients in each cohort below.
- Cohort 1: Patients with BMI < 25.0 kg/m2 treating with anastrozole
- Cohort 2: Patients with BMI ≥ 25.0-29.9 kg/m2 treating with anastrozole
- Cohort 3: Patients with BMI ≥ 30 kg/m2 treating with anastrozole
- Cohort 4: Patients with BMI < 25.0 kg/m2 treating with letrozole
- Cohort 5: Patients with BMI ≥ 25.0-29.9 kg/m2 treating with letrozole
- Cohort 6: Patients with BMI ≥ 30 kg/m2 treating with letrozole
Based on the patients' calculated BMI, patients in each BMI category (normal, overweight, and obese) will be enrolled in the different cohorts as described above. The first 15 patients in each BMI category will be treated with anastrozole. After completion of enrollment in cohorts 1, 2, and 3, subsequent patients will be treated with letrozole in cohorts 4, 5, and 6.
Anastrozole 1 mg or Letrozole 2.5 mg oral daily will be administered and continued for a minimum of 14 days and a maximum of 28 days (2-4 weeks). Surgery will be performed between weeks 2-3 of treatment unless there are compelling medical or personal reasons that prevent a patient from having surgery during this time. In those cases, patients may continue anastrozole or letrozole up to 4 weeks before surgery. Surgery should be performed within 36 hours of the last dose of anastrozole or letrozole.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Female greater than or equal to 18 years.
- •Postmenopausal status, defined by no menstrual cycle for 12 months or surgical removal of ovaries.
- •Histologically confirmed adenocarcinoma of the breast.
- •Evidence of hormone sensitive, ER rich primary tumor defined by an Allred score of ≥
- •Human estrogen receptor -2 (HER2) negative in the primary tumor tissue as defined by:
- •Grade 0 or 1+ staining intensity (on a scale of 0 to 3) by means of IHC analysis OR
- •Grade 2+ staining intensity by means of immuno-histochemical (IHC) analysis with gene amplification on fluorescence in situ hybridization (FISH) < 2.0 OR
- •Gene amplification on fluorescence in situ hybridization (FISH) < 2.
- •Eastern Cooperative Oncology Group (ECOG) performance status ≤ 3
- •Unresected operable breast cancer stage I-III with primary tumor ≥ 2.0 cm.
- •Ability to understand and the willingness to sign a written informed consent document.
- •Patients must not have received any prior chemotherapy, radiation therapy, or endocrine therapy for their current breast cancer. Patients who received tamoxifen or raloxifene or another agent for prevention of breast cancer may be included as long as the patient has discontinued the treatment at least one month prior to baseline study biopsy.
- •Patients must have an adequate tumor tissue sample prior to enrollment available for correlative studies as defined below: Core needle biopsy or incisional biopsy samples that can provide ≥ 5 unstained sections of 5 micron thickness. Fine needle aspiration (FNA) sample alone is not sufficient.
- •Patients must have adequate organ function as defined below:
- •Total bilirubin within normal institutional limits
- •aspartate aminotransferase (AST)(SGOT)/alanine aminotransferase (ALT)(SGPT) < 2.5 x institutional upper limit of normal
- •Creatinine clearance ≥ 10 mL/min/1.73 m2
排除标准
- •Previous or current systemic malignancy within the past 3 years other than breast cancer or adequately treated cervical carcinoma in situ or basal/squamous carcinoma of the skin.
- •Patients may not be receiving any other investigational agent.
- •History of allergic reactions or hypersensitivity to compounds of similar chemical or biologic composition to anastrozole or letrozole.
研究组 & 干预措施
Cohort 3: Obese
Cohort 3: Patients with BMI ≥ 30 kg/m2 treated with anastrozole
干预措施: Anastrozole (Drug)
Cohort 1: Normal Weight Anastrozole
Cohort 1: Patients with BMI < 25.0 kg/m2 treated with anastrozole
干预措施: Anastrozole (Drug)
Cohort 2: Overweight Anastrozole
Cohort 2: Patients with BMI ≥ 25.0-29.9 kg/m2 treated with anastrozole
干预措施: Anastrozole (Drug)
Cohort 4: Normal Weight Letrozole
Cohort 4: Patients with BMI < 25.0 kg/m2 treating with letrozole
干预措施: Letrozole (Drug)
Cohort 5: Overweight Letrozole
Cohort 5: Patients with BMI ≥ 25.0-29.9 kg/m2 treating with letrozole
干预措施: Letrozole (Drug)
Cohort 6: Obese Letrozole
Cohort 6: Patients with BMI ≥ 30 kg/m2 treating with letrozole
干预措施: Letrozole (Drug)
结局指标
主要结局
Percent Change in Proliferative Index (Ki67) After Treatment With the Standard Dose Anastrozole or Letrozole in Normal, Obese, and Overweight Patients
时间窗: 2-4 weeks Post-treatment
Core biopsy
次要结局
- To Evaluate Differences in Baseline GP88 Level(B,0-Prior to starting anastrozole or letrozole)
- To Evaluate Differences in Baseline GP88 Level(B,1-On the day of surgery or within 3 days of surgery)
- To Evaluate Differences in Baseline GP88 Level(B,2-obtained 2-4 weeks after initiation of AI therapy( for persons rec. extended neoadjuvant tx))
- To Assess Estradiol Levels at Baseline and After Treatment (in Primary ER Positive Breast Tumors)(Baseline)
- To Assess Estradiol Levels at Baseline and After Treatment (in Primary ER Positive Breast Tumors)(2-4 weeks Post treatment)
- To Evaluate the Association of AI-induced Ki67 Response(Baseline)
- To Evaluate the Association of AI-induced Ki67 Response(2-4 weeks Post-Treatment)
- To Evaluate Differences in Oncotype Dx(Baseline(T0))
- To Evaluate Differences in Oncotype Dx(2-4 Post-treatment)
研究者
Suliat Nurudeen
Professor of Medicine
University of Maryland, Baltimore